Audentes Therapeutics (BOLD) Announces Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Audentes Therapeutics (NASDAQ:BOLD) issued its earnings results on Tuesday. The biotechnology company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.09), Briefing.com reports. During the same period in the previous year, the company earned ($0.88) earnings per share.

Audentes Therapeutics stock traded down $5.33 during mid-day trading on Wednesday, hitting $24.23. 3,465,670 shares of the company were exchanged, compared to its average volume of 442,907. Audentes Therapeutics has a 1-year low of $19.62 and a 1-year high of $46.18. The firm has a market capitalization of $1.10 billion, a P/E ratio of -7.13 and a beta of 1.99.

Several brokerages recently commented on BOLD. Zacks Investment Research raised Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research report on Tuesday, July 10th. HC Wainwright set a $33.00 target price on Audentes Therapeutics and gave the stock a “buy” rating in a research report on Sunday, October 14th. William Blair cut Audentes Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday. Wedbush reaffirmed an “outperform” rating and issued a $49.00 target price on shares of Audentes Therapeutics in a research report on Wednesday, August 8th. Finally, ValuEngine lowered Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, October 12th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $36.00.

In other news, CEO Matthew R. Patterson sold 12,952 shares of the firm’s stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $40.00, for a total value of $518,080.00. Following the completion of the sale, the chief executive officer now directly owns 12,952 shares in the company, valued at $518,080. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Suyash Prasad sold 10,000 shares of the firm’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $36.88, for a total value of $368,800.00. Following the completion of the sale, the vice president now owns 100 shares of the company’s stock, valued at $3,688. The disclosure for this sale can be found here. Insiders have sold 77,039 shares of company stock valued at $2,925,260 over the last quarter. Corporate insiders own 6.60% of the company’s stock.

Several large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its stake in shares of Audentes Therapeutics by 2.9% in the third quarter. JPMorgan Chase & Co. now owns 117,284 shares of the biotechnology company’s stock valued at $4,644,000 after buying an additional 3,331 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Audentes Therapeutics by 7.9% in the third quarter. Wells Fargo & Company MN now owns 429,678 shares of the biotechnology company’s stock valued at $17,011,000 after buying an additional 31,523 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Audentes Therapeutics by 3.0% in the third quarter. Victory Capital Management Inc. now owns 761,361 shares of the biotechnology company’s stock valued at $30,142,000 after buying an additional 22,120 shares in the last quarter. Northern Trust Corp increased its stake in shares of Audentes Therapeutics by 48.0% in the second quarter. Northern Trust Corp now owns 368,571 shares of the biotechnology company’s stock valued at $14,083,000 after buying an additional 119,602 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Audentes Therapeutics by 32.1% in the second quarter. Bank of New York Mellon Corp now owns 127,693 shares of the biotechnology company’s stock valued at $4,879,000 after buying an additional 31,048 shares in the last quarter. Institutional investors own 96.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Audentes Therapeutics (BOLD) Announces Quarterly Earnings Results, Misses Estimates By $0.09 EPS” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/11/07/audentes-therapeutics-bold-announces-quarterly-earnings-results-misses-estimates-by-0-09-eps.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Story: What is the S&P 500 Index?

Earnings History for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply